MedPath

FDA Expedited Designations: RMAT and Fast Track Gain Traction Over Breakthrough Therapy

• Parexel's analysis reveals trends in FDA expedited designations for advanced therapies, highlighting Breakthrough Therapy Designation (BTD), Regenerative Medicine Advanced Therapy (RMAT), and Fast Track (FT). • RMAT designation, introduced in 2016, is gaining popularity, especially for cell and gene therapies, due to its lower qualifying threshold and similar benefits to BTD. • Fast Track designation sees unprecedented request levels due to minimal qualifying criteria, offering validation potential and increased FDA interactions despite limited regulatory advantages. • Strategic decision-making by developers favors RMAT and FT as more accessible alternatives to the stringent BTD, impacting the trajectory of the R&D pipeline.

Parexel's Cell & Gene Therapy Center of Excellence has released an analysis detailing the evolving trends in FDA expedited development designations for advanced therapies. The analysis focuses on three key designations overseen by the Center for Biologics Evaluation and Research (CBER): Breakthrough Therapy Designation (BTD), Regenerative Medicine Advanced Therapy (RMAT), and Fast Track (FT) designations.

Breakthrough Therapy Designation (BTD)

Established in 2012, the BTD is known for its rigorous qualification criteria. From 2012 to 2023, the grant success rate for BTD was 33%. While BTD requests experienced a decline during the pandemic, they rebounded in 2023, albeit with a lower success rate of 29%. The BTD is applicable to all CBER-regulated products, including vaccines and cell and gene therapies (CGTs).

Regenerative Medicine Advanced Therapy (RMAT)

Introduced in 2016, the RMAT designation has rapidly gained traction, particularly for CGTs. This is attributed to its relatively lower qualifying threshold compared to the BTD. The RMAT designation offers similar benefits to the BTD, such as early FDA insights and opportunities for discussions on clinical development programs, leading to a higher success rate and frequent requests surpassing those for the BTD.

Fast Track (FT) Designation

The Fast Track (FT) designation, characterized by its minimal qualifying criteria, has become the most sought-after expedited designation. Requests for FT designation have reached unprecedented levels. Despite offering limited regulatory advantages, the FT designation is valued for its validation potential and the opportunity for increased interactions with the FDA.
The analysis underscores the strategic decision-making involved for developers in selecting these designations. RMAT and FT offer more accessible alternatives compared to the stringent BTD, thereby influencing the trajectory of the R&D pipeline.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Clarifies Confirmatory Trial Requirements for Accelerated Drug Approvals

The FDA issued draft guidance clarifying requirements for confirmatory trials needed to verify clinical benefit of drugs receiving accelerated approval.
The guidance emphasizes early consultation with the FDA on trial design and the need for sponsors to commit sufficient resources for timely trial completion.

Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements

Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.
A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months.

FDA's Accelerated Approval Pathway Faces Scrutiny Amidst Withdrawals and Biomarker Concerns

The FDA's accelerated approval program, designed to expedite drug availability, faces increased scrutiny due to recent high-profile withdrawals, including Pfizer's Oxbryta.
Experts are raising concerns about the reliability of surrogate endpoints and the timeliness of confirmatory trials required for maintaining accelerated approvals.

FDA Intensifies Scrutiny of Accelerated Approvals with Stricter Confirmatory Trial Requirements

The FDA is increasing requirements for confirmatory trials to verify clinical benefits of drugs granted accelerated approval, addressing concerns about delays and patient risks.
Recent regulatory changes, including the 2022 FDORA Omnibus Act, mandate that confirmatory trials be underway before New Drug Application (NDA) submission.

FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Six Gene Therapies

The FDA has granted Rare Pediatric Disease (RPD) and Orphan Drug Designations (ODD) to six investigational gene therapies developed under the Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
These designations aim to incentivize the development of gene therapies for rare diseases affecting children, offering financial benefits such as Priority Review Vouchers and tax credits.

FDA Requires Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer's Disease

The FDA has informed Eisai Co Ltd and Biogen Inc that a Fast Track designation specific to the subcutaneous formulation of Leqembi is necessary for rolling review, altering Eisai's regulatory submission plans. Despite delays, the potential of Leqembi remains significant, with its non-subcutaneous formulation already receiving traditional FDA approval.

FDA Issues Draft Guidance to Improve Accelerated Approval Applications

The FDA has released draft guidance aimed at enhancing the quality of applications for accelerated approvals, particularly for oncology drugs.
The guidance emphasizes the importance of timely postmarketing confirmatory studies to reduce clinical uncertainty and ensure patient benefit.

FDA Intensifies Scrutiny on Accelerated Approvals for Cancer Drugs, Mandating Earlier Confirmatory Trials

The FDA is increasing its requirements for accelerated approvals of cancer drugs, emphasizing the need for companies to have comprehensive confirmatory trial plans upfront.
The Oncology Center of Excellence now wants to see confirmatory trials underway when companies submit applications for accelerated approvals, potentially impacting smaller biotechs.

Overview of Advanced Therapy Medicinal Products (ATMPs) in the European Union

This article provides a comprehensive overview of Advanced Therapy Medicinal Products (ATMPs) within the European Union, including those available via centralized marketing authorization or national Hospital exemption. It also forecasts innovative ATMPs in the process of EMA approval and those in phase III and IV clinical trials, highlighting the evolving landscape of personalized medicinal strategies.

Reference News

[1]
Parexel Introduces FDA Expedited Designation Trends For Advanced Therapies
clinicalleader.com · Nov 19, 2024

Parexel’s Cell & Gene Therapy Center of Excellence analyzes FDA expedited designations (BTD, RMAT, FT) for advanced ther...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy